A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

Launched by MIND MEDICINE, INC. · Jan 30, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called MM120 for people with Generalized Anxiety Disorder (GAD), which is a condition where individuals often feel excessive worry or anxiety about everyday situations. The trial is in its final phase, known as Phase 3, and aims to see how effective MM120 is compared to a placebo (a fake treatment that doesn’t contain any active medication) in helping to reduce anxiety symptoms.

To participate in this study, individuals need to be between 18 and 74 years old and must have a diagnosis of GAD, confirmed by specific criteria. The study is currently recruiting participants, and those who join can expect to be randomly assigned to receive either MM120 or the placebo. This means that neither the participants nor the researchers will know who is receiving the actual treatment, helping to ensure the study's results are unbiased. It's also important to note that individuals with other major psychiatric disorders or certain health issues may not be eligible to participate. Overall, this trial could contribute valuable information about new options for treating anxiety.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosis of GAD per DSM-5
• • 2. Male or female aged 18 to 74
• • 3. HAM-A Total Score ≥20
• Exclusion Criteria:
• • 1. Certain psychiatric disorders (other than generalized anxiety disorder)
• • 2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
• • 3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
• • 4. Any clinically significant unstable illness